Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA.

European journal of cancer (Oxford, England : 1990) - 1 May 1999

Dørum A, Hovig E, Tropé C, Inganas M, Møller P

Abstract excerpt

Our aim was to determine the prevalence of two Norwegian BRCA1 founder mutations in ovarian cancer patients, to identify carriers and their families for medical follow-up, and to study histopathological factors. Of a cohort of 727 ovarian cancer patients, 615 gave informed consent to testing. 2.9% (18/615) of the tested patients were found to be carriers of BRCA1 1675delA (n = 13) or 1135insA (n = 5). The total...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age of Onset
Share to Breast Neoplasms
Share to Founder Effect

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Norway

Share to Ovarian Neoplasms

Share to Prevalence

Share to Prognosis

Source

Identifiers

PMID: 10505039
DOI: 10.1016/s0959-8049(99)00050-7

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA.PMID 10505039Read ↗

BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.Semantic proximity Read ↗

Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.Semantic proximity Read ↗

The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.Semantic proximity Read ↗

BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.Semantic proximity Read ↗

BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study.Semantic proximity Read ↗

BRCA mutation testing and association with oncologic outcome and incidence of ovarian cancer in Norway.Semantic proximity Read ↗

One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.Semantic proximity Read ↗

BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.Semantic proximity Read ↗

Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.Semantic proximity Read ↗

Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.Semantic proximity Read ↗

BRCA1 Norway: comparison of classification for BRCA1 germline variants detected in families with suspected hereditary breast and ovarian cancer between different laboratories.Semantic proximity Read ↗

BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.